Sofinnova Ventures — 2025 Investments
6 investments dated 2025 · listed companies and verified rows first · show all
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
Board seatDavid Kabakoff· per SEC Form D
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+2 more
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatLars Ekman· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsvenBio PartnersvenBio Global Strategic
Durham, US
Board seatChris CarpenterJames Healy· per SEC Form D · $150M raise · filed Apr 2025
BiotechCleveland, US
Arnon Chait(Executive Officer, Director)ANDREW SUMMERS(Executive Officer)
BoardJOSEPH RICH(Director)SAMEER ROHATGI(Director)DARA WRIGHT(Director)
Board seatNoel Jee· per SEC Form D · $14.4M raise · filed Oct 2025
Co-investorsJobsOhio VenturesJumpstart VenturesLYFE Capital
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inJason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)
Board seatMaha Katabi· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesAgent CapitalBlue Owl Capital+8 more
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Jonathan Freeman(Interim CEO)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalAlexandriaB CapitalQatar Investment Authority+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.